As of June 28, 2025, Graybug Vision Inc (GRAY) reports a ROE (Return on Equity) of -98.98%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Graybug Vision Inc's ROE (Return on Equity)
Over recent years, Graybug Vision Inc's ROE (Return on Equity) has shown a stable trend. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2022-12-31 | -98.98% |
| 2021-12-31 | -55.09% |
| 2020-12-31 | -29.04% |
| 2019-12-31 | -130.42% |
| 2018-12-31 | -236.50% |
This fluctuation highlights how Graybug Vision Inc manages its efficiency in generating profits from shareholders' equity over time.
Comparing Graybug Vision Inc's ROE (Return on Equity) to Peers
To better understand Graybug Vision Inc's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Graybug Vision Inc (GRAY) | -98.98% |
| Hepion Pharmaceuticals Inc (HEPA) | 708.00% |
| Iterum Therapeutics PLC (ITRM) | 612.59% |
| Eloxx Pharmaceuticals Inc (ELOX) | 338.32% |
| Baudax Bio Inc (BXRX) | 242.57% |
| Weed Inc (BUDZ) | 231.08% |
Compared to its competitors, Graybug Vision Inc's ROE (Return on Equity) is among the lowest compared to peers, which may indicate less effective deployment of shareholders' capital.